| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -25.4 | -26.5 |
| EPS (diluted, $ a share) | $-0.35 | $-0.44 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ABOS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Acumen Pharmaceuticals, Inc.: key numbers
- Share price
- $0.2160Close, Nov 16
- Market cap
- $15.6M
- Shares outstanding
- 72.33MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Acumen Pharmaceuticals, Inc.
All →Acumen Pharmaceuticals Business Update
Acumen Pharmaceuticals is implementing a major restructuring plan that includes reducing its workforce by approximately 90% (52 employees) following the decision to cease development of its lead candidate, sabirnetug. The company estimates it will incur $7.75 million in severance-related charges and has also fully repaid its $23.3 million outstanding debt to K2 HealthVentures to conserve cash while evaluating strategic options.
Acumen Pharmaceuticals Clinical Trial Data
Acumen Pharmaceuticals announced that its Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer’s disease failed to meet its primary endpoint of cognitive and functional decline improvement. The trial also failed key secondary endpoints, leading the company to cease development of sabirnetug and implement cash conservation measures while exploring strategic options.
- Term
- 18 months
Acumen Pharmaceuticals Financial Results
Acumen Pharmaceuticals reported third quarter 2026 financial results, highlighting a cash position of $78.6 million which is expected to fund operations into early 2027. The company announced it expects to report topline results from its ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer’s disease in November 2026.
- Term
- Q3 2026
“In the third quarter, we continued readying for the readout from our ALTITUDE-AD Phase 2 study investigating the efficacy, safety and tolerability of sabirnetug for the treatment of early AD, and today I’m pleased to announce that we expect to report topline results in November 2026. We remain encouraged by the potential for sabirnetug to become a treatment of choice, with a differentiated benefit-risk profile driven by its unique attributes as an anti-AβO IgG2 monoclonal antibody.”
Daniel O’Connell, Chief Executive Officer of Acumen
Acumen Pharmaceuticals Investor Presentation
Acumen Pharmaceuticals is hosting an Investor Day on September 16, 2026, to discuss its strategic goals and clinical pipeline, including its product candidate sabirnetug (ACU193) for Alzheimer's Disease. The presentation covers the Phase 2 ALTITUDE-AD study, potential subcutaneous dosing options, and the company's Enhanced Brain Delivery (EBD) technology with a planned IND filing in mid-2027.